XML 80 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1
License and Collaboration Agreements - Additional Information (Detail)
1 Months Ended 12 Months Ended 50 Months Ended
Nov. 30, 2020
USD ($)
Oct. 27, 2020
USD ($)
Jan. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Apr. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2022
USD ($)
Aug. 31, 2021
USD ($)
Jun. 30, 2021
Program
Dec. 31, 2024
USD ($)
License
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
USD ($)
License
Jul. 31, 2021
USD ($)
Jan. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Development cost reimbursement received     $ 15,000,000                            
Royalties receivable                     $ 4,525,000 $ 3,054,000   $ 4,525,000      
Number of licensed products | License                     2     2      
Accrued expenses                     $ 140,184,000 127,806,000   $ 140,184,000      
Up-front payment on first anniversary of agreement on June 30, 2022             $ 25,000,000                    
SYFOVRE [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Royalty expense                     19,800,000 8,900,000          
Regulatory milestone payments     3,000,000 $ 2,000,000 $ 2,300,000                        
Regulatory milestone incurred                       5,000,000          
Empaveli And Aspaveli [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Milestone payments based on annual sales milestones     1,500,000                            
Royalty expense                     6,400,000 4,800,000 $ 2,700,000        
Swedish Orphan Biovitrum AB (Publ) [Member] | Aspaveli [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Royalty revenue                     $ 18,400,000 10,000,000 $ 3,000,000        
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payment $ 250,000,000                                
Milestone payment received for achievement of regulatory development milestone               $ 50,000,000                  
Development cost reimbursement received           $ 65,000,000                      
Waived Payment     15,000,000                     15,000,000      
Royalties entitled to receive after first commercial sale of applicable licensed product period                     10 years            
Revenue recognized                     $ 53,000,000 15,300,000          
Contract research and development expense                     0     65,000,000      
Remaining reimbursement payment     15,000,000                            
Contract research and development reimbursement commitment   $ 80,000,000                              
Contract research and development current                       $ 15,000,000          
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events                                 $ 915,000,000
Development cost reimbursement                     80,000,000            
University of Pennsylvania [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Development milestone achievement             $ 5,000,000   $ 1,000,000                
University of Pennsylvania [Member] | Empaveli And Aspaveli [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Milestone payments based on annual sales milestones           $ 1,000,000                      
University of Pennsylvania [Member] | Maximum [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Aggregate milestones payments                     3,200,000     3,200,000      
Milestone payments based on annual sales milestones                     5,000,000            
2010 License Agreement [Member] | Maximum [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Aggregate milestones payments                     1,700,000     $ 1,700,000      
Milestone payments based on annual sales milestones                     $ 2,500,000            
Sobi Agreement and Another Licensing Transaction [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Sublicense fee owed     $ 500,000                         $ 25,000,000  
Research Collaboration Agreement [Member] | Beam [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Collaboration agreement term                   5 years              
Number of research programs | Program                   6              
Up-front non-refundable payment                             $ 50,000,000    
Collaboration agreement maximum extendable term             2 years